^
    Back
    Association details:
    Biomarker:CD34 positive + MN1 overexpression + MCL1 elevation
    Cancer:Acute Myelogenous Leukemia
    Drug:S63845 (MCL1 inhibitor) +
    unesbulin (BMIi-1) (BMI1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancers (Basel)
    Title:

    BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia

    Published date:
    02/02/2021
    Excerpt:
    BMI1 and MN1 gene expression, and MCL1 and MEK1 protein levels were identified as biomarkers for response to PTC596 combination treatments. The combination of PTC596 and S63845 may be an effective treatment in CD34+ adverse risk AML with elevated MN1 gene expression and MCL1 protein levels...
    DOI:
    10.3390/cancers13030581